| 5-ASA | 5-aminosalicylic acid (mesalazine/mesalamine) |
| ADA | adalimumab |
| AZA | azathioprine |
| BD | Behçet’s disease |
| CENTRAL | Cochrane Central Register of Controlled Trials |
| CINAHL | Cumulative Index to Nursing and Allied Health Literature |
| COL | colchicine |
| CS | corticosteroids |
| CSA | cyclosporine A |
| CYC | cyclophosphamide |
| EN | enteral nutrition |
| ETN | etanercept |
| GI | gastrointestinal |
| GI-PedBD | gastrointestinal involvement in pediatric Behçet’s disease |
| IBD | inflammatory bowel disease |
| ICBD | International Criteria for Behçet’s Disease |
| IFX | infliximab |
| ISG | International Study Group (criteria) |
| JBI | Joanna Briggs Institute |
| MMF | mycophenolate mofetil |
| MPDN | methylprednisolone |
| MTX | methotrexate |
| PDN | prednisolone/prednisone |
| PedBD | pediatric Behçet’s disease |
| PEDBD | Pediatric Behçet’s Disease (classification criteria) |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| SSZ | sulfasalazine/salazosulfapyridine |
| TAC | tacrolimus |
| THAL | thalidomide |
| TNF | tumor necrosis factor |
| TPN | total parenteral nutrition |